Literature DB >> 1471384

Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis.

H Kellner1, W G Zoller.   

Abstract

In order to assess the effectiveness of cytapheresis as a possible alternative therapy for iron depletion, we performed a prospective study on eight unrelated patients with idiopathic hemochromatosis (HC). Isovolemic large-volume erythrocytapheresis (EA) (1000 ml apherisate) was carried out every four weeks until serum ferritin levels dropped below 300 micrograms/l (initial therapy). In all patients iron depletion was achieved after a mean of 8.5 months (8.9 EA with a total removal of 9.41 RBC). Serum ferritin levels decreased during initial therapy from 2596 +/- 399 to 168 +/- 83 ug/l. Serum iron level (240 +/- 35 to 125 +/- 48 ug/dl) and transferrin saturation (91 +/- 6 to 19 +/- 10%) declined accordingly. Clinical reexamination after initial therapy revealed improvement of clinical symptoms, normalization of hepatic iron, but liver histology remained unchanged. Reaccumulation of iron was prevented by maintenance EA therapy every five to six months (follow-up 18-36 months). Isovolemic large-volume EA is an effective, fast and safe method to remove excessive stored iron in patients with HC. Compared to phlebotomy, EA can selectively remove RBC, while saving plasma proteins, platelets, and clotting factors. Although, the need for special equipment and trained personnel as well as the relatively high costs are limiting factors of EA so far, it can be of crucial advance in some patients with HC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471384

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  5 in total

1.  Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.

Authors:  Tatjana Sundic; Tor Hervig; Signe Hannisdal; Jörg Assmus; Rune J Ulvik; Richard W Olaussen; Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-10-23       Impact factor: 3.443

Review 2.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

4.  High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease.

Authors:  Janette Bester; Antoinette V Buys; Boguslaw Lipinski; Douglas B Kell; Etheresia Pretorius
Journal:  Front Aging Neurosci       Date:  2013-12-06       Impact factor: 5.750

5.  A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.

Authors:  Eva Rombout-Sestrienkova; Bjorn Winkens; Marian van Kraaij; Cees Th B M van Deursen; Mirian C H Janssen; Alexander M J Rennings; Dorothea Evers; Jean-Louis Kerkhoffs; Ad Masclee; Ger H Koek
Journal:  J Clin Apher       Date:  2020-12-24       Impact factor: 2.821

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.